***CV 1-page Summary***

**Personal Information**

**Name:** Mahdi Fallah **Nationality:** German

**Email**: Mahdi.fallah@uib.no / [m.fallah@dkfz.de](mailto:m.fallah@dkfz.de)

***Degrees:*** Medical Doctorate (**MD**), and **PhD** in **Epidemiology**

***Publications***

* **>80** peer-reviewed **publications** (excluding abstracts/posters)
* Recent papers in top medical journals, such as ***JNCCN***, ***Am J*** **G*astroenterol***, ***PLOS Med*** (×2), ***PNAS***, ***Leukemia*** (×2)***, Blood, Ann Oncol*** (×2)***, Eur Urol,* G*astroenterol, JAMA Oncol*** (×2)***, BMJ*** (×2),& ***JCO*** [impact factors **9**, **10, 10.5,12, 17, 18, 19, 25, 30**, **33**]
* PhD monograph, MD thesis & a book; h-index=25; i10-index=50; **>2500** **times** [**cited**](https://scholar.google.com/citations?user=T5i6hacAAAAJ&hl=en)

***Experiences***

* **2021-present**: Permanent **full Professor in Medicine (Epidemiology)**, University of Bergen, Norway
* **2015-present: Group Leader (Tenured), Risk Adapted Cancer Preve­ntion Group,** Division of Preventive Oncology, National Center for Tumor Diseases, German Cancer Research Center (DKFZ)
* **2013-2015: Head, Epidemiology Research Group**, Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
* **2007-present:** Working on huge **real-world data from Europe in collaboration with US**
* **Scientist and coordinator** of **Nordic** collaboration on familial cancers; **5 years clinical practice**;
* 3 years **pharmaco-epidemiologist** in chronic diseases epidemiology in Finland
* Extensive **research** experience & internationalcollaborations **(UK, EU, North America, Asia)**
* Pooling & analysis of **huge international** **datasets** (various cancer registries, Nordic Family-Cancer datasets, and **Swedish Family-Cancer Datasets**, **world's largest** ones, with >16 million subjects including **Inpatient/Outpatients Registers (>165 million records)**; Medical **Birth Register** with >4.7 million pregnancy records; and **Prescription Register** with >800 million drug dispenses)
* **Supervising / mentoring / teaching / evaluating** PhD students and post-docs

***Highlights***

* Felix Burda **Award** Nominee **2020** (final winner TBA in 2021, Berlin, Germany)
* **AACR Awards 2015 and 2016;** **Best Article Award;** several **press releases** & **grants** & **CME Exams**
* **Developed** familial **Prostate** **Cancer** **Risk Assessment Model** (**PCRAM**) and **several methods** in cancer epidemiology; expert in **SAS** statistical package
* Development & analysis of **large-scale health record databases** (real world data)
* **Reviewer of** Membership (**Professorship**), Memorial Kettering Cancer Center, **USA**
* **Reviewer of nomination for** Canada Research Chair (**Professorship**), Ottawa**, Canada**
* **Reviewer of grant application:** Swiss Cancer League, **Swiss Cancer Research, Switzerland**
* **Reviewer of grant application: Cancer Research UK** (**largest** charitable funder of cancer research **in the world**), **UK**
* **Editorial Board Member/Reviewer of peer-reviewed journals***:* ***NEJM,******J Clin Oncol, JAMA Oncol, Ann Oncol****,* ***JNCI****,* ***Medicine****,* ***JAMA*** *Dermatol,* ***Cancer****,* ***Int J Cancer****,* ***Eur J Epidemiol****,* ***Thyroid****,* etc.
* **Reviewer of** abstracts of 24th Congress of **European Association for Cancer Research (EACR)** 2016
* **Reviewer of Posters**, DKFZ Annual PhD Poster Presentation & Poster Prizes

**CV in Details**

**Personal Information**

**Name:** Mahdi Fallah **Nationality:** German

**Email**: Mahdi.fallah@uib.no / [m.fallah@dkfz.de](mailto:m.fallah@dkfz.de)

**Education**

2003 - 2007 **PhD** Epidemiology University of Tampere, Tampere, Finland

1991 - 1999 **MD** Medical doctorate Isfahan University of Medical Sciences, Isfahan, Iran

**Positions and Employment**

2021 – Pres Permanent full **Professor in Medicine** (Epidemiology), University of Bergen, Norway

2015 – Pres **Group Leader (Tenured),** Risk Adapted Cancer Prevention Group, Division of Preventive Oncology, National Center for Tumor Diseases (NCT), **German Cancer Research Center (DKFZ)**, Heidelberg, Germany

2013 – 2015 **Head, Epidemiology Group**, Division of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg, Germany

2011 Sep-Dec **Visiting Scientist**, Finnish Cancer Registry, Helsinki, Finland

2010 – 2015 **Scientist** and **Coordinator**, Collaboration Project on Familial Cancer in Nordic Countries, German Cancer Research Center, Heidelberg, Germany

2009 – Pres **Research Fellow**, Lund University, Dep. of Clinic. Sciences, Malmö, Sweden

2009 – 2013 **Scientist**, German Cancer Research Center, Heidelberg, Germany

2007 – 2009 **Pharmaco-epidemiologist**, Tampere University Hospital, Finland

2007 **Assistant Professor** (TA), School of Public Health, University of Tampere, Finland

2002 – 2003 **Research Fellow**, Digestive Diseases Research Institute, Tehran, Iran

1999 – 2002 **Physician**, Kashan University of Medical Sciences, Kashan, Iran

**Awards and Honors**

2020 **Felix Burda Award** Nominee2020(final winner TBA in 2021)

2020 ***Gastroenterology*** paper selected for **US Continuing Medical Education** (I prepared CME Exam)

2020 **Press Release**, *NCT* and *DKFZ*(***Gastroenterology*** paper is inscientific news since 5Apr2020)

2020 **Press Release**, *NCT* and *DKFZ*(***Am J*** ***Gastroenterology*** paper is innews e.g., ***Reuters***/***Medscape***)

2020 **Press Release**, *NCT* and *DKFZ*(***PLoS Med*** paper is in ***Reuters*** news and Medscape)

2020 **Press Release**, *NCT* and *DKFZ*(***BMC Med*** paper is in ***Reuters*** news and Medscape)

2020 **Press Release**, *NCT* and *DKFZ*(***Cancer*** paper is innews since Aug 2020)

2019 **Press Release**, *NCT* and *DKFZ*(***JAMA Oncology*** paper was inscientific news)

2019 **Press Release**, *NCT* and *DKFZ*[***BMJ*** paper was in scientific news *(e.g.,* ***ASCO,******Medscape****, MDLinx, etc.)* and general news websitessuch as ***Reuters***]

2017 **Press Release** on our Register-based studies by *NCT* and *Ulm University* went to German news

2016 **AACR**-GYRIG **Award**, *American Association for Cancer* *Research* (AACR), USA

2015 **AACR**-Pezcoller Foundation **Award**, *American Association for Cancer* *Research* (AACR), USA

2015 My paper selected for *American Society of Hematology* (ASH) **Clinical News**, ***Blood*** journal

2015 My paper selected as “**Highlight of the Month**”*,* ***Eur Urol*** journal (IF2017: 18)

2015 My paper selected for**EU & US Continuing Medical Education** (ACME & CME*),* ***Eur Urol***

2012 **Press Release**, ***BMJ*** (reported in thousands of websites including Medscape)

2008 **Press Release**, *The 62nd Annual Meeting of the American Epilepsy Society*, Seattle, USA

2007 Best Article **Award**, *The 19th Asia Pacific Cancer Conference*

**Other Experiences and Professional Memberships**

2020 **Reviewer of grant application: Cancer Research UK (largest** charitable funder of cancer research **in the world), UK**

2019 **Reviewer** of nomination for Canada Research Chair (**Professorship**), Canada

2018 **Reviewer** of Membership (**Professorship**), Memorial Sloan Kettering Cancer Center (MSK), **New York**, USA

2016 – 2019 **Member**, American Society of Clinical Oncology (**ASCO**), USA

2016 – Pres **Chair**/**Member**, PhD **Thesis Advisory Committee (TAC)** for several students, German Cancer Research Center, Germany

2016 & 2017 **Reviewer of posters**, DKFZ Annual PhD Poster Presentation and Poster Prizes

2016 **Reviewer of abstracts** for 24th Biennial Congress of the European Association for Cancer Research(**EACR**), Manchester, UK

2015 **Reviewer of grant application**, Swiss Cancer League, Swiss Cancer Research, Switzerland

2015 – Pres **Editorial Board Member**, *International Journal of Epidemiologic Research*

2015 – Pres **Editor**, *Journal of Thyroid Cancer*

2013 – 2015 International Multidisciplinary Community Genetics Network

2012 – Pres **Member**, Selection of Helmholtz International Graduate School for Cancer Research (DKFZ PhD candidate selection, **Chair of** Presentation Review **Panel**, and General Interview Panel)

2012 – Pres **Member**, American Association for Cancer Research (**AACR**), USA

2010 – Pres Interactive Network of **Senior Scientists** (INESS), German Cancer Research Center

2009 – Pres **Reviewer** **of** following selected **peer-review journals**:

* ***NEJM*** (IF 75)
* ***J Clin Oncol*** (IF 33)
* ***JAMA Oncol*** (IF 25)
* ***Annals of Oncology*** (IF 18)
* ***J Natl Cancer Inst*** (IF 12)
* ***Cancer***
* *International J Cancer*
* ***JAMA*** *Dermatology*
* *Eur J Epidemiology*
* *Cancer Epidemiol Biomar Prev*
* *Cancer Epidemiology*
* *Medicine*
* *Thyroid*
* *Hematology Reports*
* *Cancer Research Frontiers*
* *BMC Cancer*
* *J Pediatric Surgery*
* *etc.*

2008 **Member**, Finnish Union of University Researchers and Teachers (FUURT), Finland

1999 – 2003 **Member**, Iran Medical Council

**Publications in brief**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| * **>80** peer-reviewed **original** publications (excluding letters and >50 abstracts/posters) * Recent papers in top medical journals such as ***JNCCN***, ***Am J*** **G*astroenterol***, ***PLOS Med*** (×2), ***PNAS***, ***Leukemia*** (×2)***, Blood, Ann Oncol*** (×2)***, Eur Urol,* G*astroenterol, JAMA Oncol*** (×2)***, BMJ*** (×2),& ***JCO*** [impact factors **9**, **10, 10.5,12, 17, 18, 19, 25, 30**, **33**] | | | | |
| * PhD monograph, MD thesis, a book, and >20 international presentations * Citations: H-index=25; i10-index=50; >**2500 times cited** * Authorship:   + Corresponding author: 34 papers + 4 ongoing + >31 abstracts   + First/co-first(=) principal author: 21 papers + 1 ongoing + >9 abstracts   + Last/co-senior(=) responsible author: 20 papers + 3 ongoing + >23 abstracts   + Second principal author: 20 papers + 1 ongoing + >5 abstracts | | | | |
| **Publications** (Selectedout of >80) | | **IF** | ***Cited*** | **Authorship** | |
| * Mukama T, Kharazmi E, Xu X, Sundquist K, Sundquist J, Brenner H, **Fallah M**. Risk-adapted starting age of screening for relatives of patients with breast cancer. ***JAMA Oncol*** 2020 6(1):68-74 (**Press released** by NCT/DKFZ; Selected as highlight publication of DKFZ). | | **25** |  | Last | |
| * Tian Y, **Fallah M=(equal contribution)**, Brenner H,Xu X, Sundquist K, Sundquist J, Kharazmi E**=**. Calculating starting age for screening in relatives of patients with colorectal cancer based on data from large nationwide datasets. ***Gastroenterology*** 2020 159:159–168 (**Press released** by NCT/DKFZ; Selected as highlight publication of DKFZ; Selected by Editor in chief for US CME). | | **19** |  | Co-senior  Corresponding  (**C**) | |
| * Xu X, Kharazmi E, Tian Y, Mukama T, Sundquist K, Sundquist J, Brenner H, **Fallah M**. Risk of prostate cancer in relatives of prostate cancer patients in Sweden: A nationwide cohort study. ***PLOS Med*** 2021 (In Press, Selected as highlight publication of DKFZ; **Press released** by the journal). | | **10.5** |  | Last  C | |
| * Ali Khan U, **Fallah M=**, Tian Y, Sundquist K, Sundquist J, Brenner H, Kharazmi E**=**. Risk of colorectal cancer in patients with diabetes mellitus: A Swedish nationwide cohort study. ***PLOS Med*** 2020 17 (11), e1003431 (**Press released** by NCT/DKFZ and Reuters News). | | **10.5** |  | Co-senior  C | |
| * Ali Khan U, **Fallah M=**, Tian Y, Sundquist K, Sundquist J, Brenner H, Kharazmi E**=**. Personal history of diabetes as important as family history of colorectal cancer for risk of colorectal cancer: A nationwide cohort study. ***Am J Gastroenterol*** 2020 115(7):1103-1109 (**Press released** by NCT/DKFZ; Reuters Health News and Medscape report on it). | | **10** |  | Co-senior  C | |
| * **Fallah M,** Mukama T, Kharazmi E. Determining the Appropriate risk-adapted screening age for familial breast cancer—Reply. ***JAMA Oncol*** 2020 ;6(6):934-935. | | **25** |  | 1st  C | |
| * Tian Y, Kharazmi E**=**, Sundquist K, Sundquist J, Brenner H, **Fallah M**=. Family history of colorectal carcinoma in situ as important as family history of invasive colorectal cancer: A nationwide cohort study. ***J Natl Compr Canc Netw*** 2021 (In press). | | **9** |  | Last  C | |
| * Mukama T, **Fallah M=,** Xu X, Sundquist K, Sundquist J, Brenner H, Kharazmi E**=**. Risk of invasive breast cancer in relatives of patients with breast carcinoma in situ. ***BMC Med*** 2020 18(1):295 (**Press released** by NCT/DKFZ; Reuters News Report in preparation; IF2019=8) | | 8 |  | Co-senior  C | |
| * Mukama T, **Fallah M=,** Tian Y, Sundquist K, Sundquist J, Brenner H,Kharazmi E**=**. Risk-tailored starting age of breast cancer screening based on reproductive factors: A nationwide cohort study. ***Eur J Cancer*** 2020 124:207-213. | | 7 |  | Co-senior  C | |
| * Xu X, **Fallah M=**, Tian Y, Sundquist K, Sundquist J, Brenner H, Kharazmi E**=**. Risk of invasive prostate cancer and prostate cancer-specific death in relatives of patients with prostatic borderline or in situ neoplasia: A nationwide cohort study. ***Cancer*** 2020 ;126(19):4371-4378 (**Press released** by NCT/DKFZ). | | 6 |  | Co-senior  C | |
| * Mukama T, **Fallah M=**, Sundquist K, Sundquist J, Brenner H, Kharazmi E**=**. Breast cancer screening for women with family history of ovarian cancer and other discordant cancers: A nationwide cohort study. ***Cancer*** 2021 (doi: 10.1002/cncr.33456) | | 6 |  | Co-senior  C | |
| * Mukama T, Kharazmi E, Sundquist K, Sundquist J, Brenner H, **Fallah M**\*. Familial risk of breast cancer by dynamic, accumulative, and static definition of family history. ***Cancer*** 2020 126:2837-2848. | | 6 |  | Last  C | |
| * Tian Y, Kharazmi E, Sundquist K, Sundquist J, Brenner H, **Fallah M**. Familial colorectal cancer risk in half siblings and siblings: nationwide cohort study. ***BMJ*** 2019 364:1803 (**Press released** by NCT/DKFZ; Selected as highlight publication of DKFZ; **Reuters** Health and many other websites; abstract **awarded by AACR**). | | **30** | *12* | Last  C | |
| * **Fallah M=**, Kharazmi E**=**, Pukkala E, Tretli S, Olsen JH, Tryggvadottir L, Sundquist K, Hemminki K. Familial risk of non-Hodgkin lymphoma by sex, relationship, age at diagnosis and histology: a joint study from five Nordic countries. ***Leukemia.*** 2016 30(2):373-8 (IF2016: 12). | | **12** | *17* | 1st  C | |
| * Kharazmi E, Hemminki K, Pukkala E, Sundquist K, Tretli S, Olsen JH, Tryggvadottir L, **Fallah M**. Cancer risk in relatives of testicular cancer patients by histology type and age at diagnosis: A joint study from five Nordic countries. ***Eur Urol*** 2015 68(2):283-9 (selected for CME credit). | | **18** | *>30* | Last | |
| * **Fallah M=**, Kharazmi E**=**, Pukkala E, Olsen JH, Tryggvadottir L, Sundquist K, Tretli S, Hemminki K. Risk of familial classical Hodgkin lymphoma by relationship, histology, age, and sex: A joint study from five Nordic countries. ***Blood*** 2015 126(17):1990-5 (**Press released** by the American Society of Hematology Clinical News). | | **17** | *>30* | 1st  C | |
| * Hemminki K, **Fallah M,** Hemminki A. Collection and use of family history in oncology clinics. ***J Clin Oncol*** 2014 32(29):3344-5. | | **33** |  | 2nd | |
| * **Fallah M**, Liu X, Ji J, Försti A, Sundquist K, Hemminki K. Hodgkin lymphoma after autoimmune diseases by age at diagnosis and histological subtype. ***Ann Oncol*** 2014 25(7):1397-404. | | **18** | *45* | 1st  C | |
| * **Fallah M**, Liu X, Ji J, Försti A, Sundquist K, Hemminki K. Autoimmune diseases associated with non-Hodgkin lymphoma: a nationwide cohort study. ***Ann Oncol*** 2014 25(10):2025-30. | | **18** | *>140* | 1st  C | |
| * **Fallah M=**, Chen T**=**, Kharazmi E, Ji J, Sundquist K, Hemminki K. Effect of a detailed family history of melanoma on risks for other tumors: A cohort study based on the nationwide Swedish Family-Cancer Database. ***J Invest Dermatol*** 2014 134(4):930-6 (IF2015: 7; ***Nature*** journals). | | 7 | *22* | 1st  C | |
| * **Fallah M**, Pukkala E, Sundquist K, Tretli S, Olsen JH, Tryggvadottir L, Hemminki K. Familial melanoma by histology and age: joint data from five Nordic countries. ***Eur J Cancer*** 2014 50(6): 1176-1183. | | 7 | *20* | 1st  C | |
| * Chen T, Hemminki K, Kharazmi E, Sundquist K, **Fallah M**. Multiple primary (even in situ) melanomas in a patient pose significant risk to family members. ***Eur J Cancer*** 2014 50(15):2659-67. | | 7 | *25* | Last | |
| * **Fallah M**, Pukkala E, Tryggvadottir L, Olsen JH, Tretli S, Sundquist K, Hemminki K. Risk of thyroid cancer in first-degree relatives of patients with non-medullary thyroid cancer by histology type and age at diagnosis: a joint study from five Nordic countries. ***J Med Genet*** 2013 50(6):373-82 (IF2010: 7; ***BMJ*** journals). | | 7 | *>40* | 1st  C | |
| * Roudgari H, Hemminki K, Brandt A, Sundquist J, **Fallah M**. Prostate cancer risk assessment model: A scoring model based on the Swedish Family-Cancer Database. ***J Med Genet*** 2012 49(5):345-352 (IF2010**: 7;** ***BMJ*** journals). | | 7 | *12* | Last  C | |
| * Kharazmi E, **Fallah M**, Sundquist K, Hemminki K. Familial risk of early and late onset cancer: nationwide prospective cohort study. ***BMJ*** 2012 345:e8076 (Selected for **BMJ press release** on 21 Dec 2012: Cancer diagnosis later in life poses significant risk to offspring). | | **30** | ***65*** | 2nd | |
| * **Fallah M**, Kharazmi E, Thomsen H, Sundquist J, Hemminki K. Determinants of unfavorable presentation of primary cutaneous melanoma. ***J Am Acad Dermatol*** 2011 65(1):e5–6. | | 8 |  | 1st  C | |
| * **Fallah M**, Kharazmi E. Substantial under-estimation in cancer incidence estimates for developing countries due to under-ascertainment in elderly cancer cases. ***Cancer Letters*** 2008 264(2):250–55. | | 7 | *12* | 1st  C | |
| **PhD Monograph, MD Thesis, and Book,** |
| * ***PhD monograph***: **Fallah M**. Cancer Incidence in Five Provinces of Iran, 1996–2000. *Acta Universitatis Tamperensis*, Faculty of Medicine at University of Tampere, Tampere, Finland 2007:1–193(***>30*** times cited). | | | | 1st & Last  C | | |
| * ***MD thesis:* Fallah M**. Young couples’ attitude towards gender and desired number of children. Department of Community Medicine, Isfahan University of Medical Sciences, Iran, 1999. | | | | 1st & Last  C | | |
| * ***Book:* Fallah M**. Girl or boy? A Scientific Method of Sex Preselection. Arghanoon Publication, Tehran, Iran, 1998, reprinted in 2000, 2002, and 2006, pp 1–384. | | | | 1st & Last  C | | |

**Near Publication/Submitted Manuscripts**

|  |  |  |
| --- | --- | --- |
| 1. Mukama T, Teerlink C; Allen-Brady K, Kharazmi E, Cannon-Albright L, **Fallah M**. Risk-adapted starting age of screening for women with family history of breast cancer: A cohort study. ***BMJ*** 2020 (under review) | **30** | Last  C |

|  |
| --- |
| **Ongoing Manuscripts** |
| 1. Kharazmi E, Xu X, Tian Y, Sundquist K, Sundquist J, **Fallah M**. Risk of prostate cancer among maternal and paternal second-degree relatives. | | Last  C |  |
| 1. Mukama T, Teerlink C; Kharazmi E, Liang Q, Cannon-Albright L, **Fallah M**. Risk-adapted starting age of screening for relatives of patients with colorectal cancer: A US cohort study. | |  |  |
| 1. Xu X, **Fallah M=**, Tian Y, Mukama T, Sundquist K, Sundquist J, Kharazmi E**=**.Familial clustering of prostate cancer with other cancers: Evidence from a nationwide cohort study | | Co-senior  C |
| 1. Kharazmi E, **Fallah M**, Sundquist K, Hemminki K. Familial risk of discordant cancer in peritoneal mesothelioma patients. | | 2nd |  |
| 1. **Fallah M**,Kharazmi E. Cancer-wise age: A novel way of risk communication and exchange between risk prediction models. | | 1st  C |  |

# Selected Presentations (out of >30)

**Session chair:** *Science@DKFZ Seminar Series,* ***Heidelberg****,* Germany, 2021

**Invited speaker:** *Cancer Epidemiology Symposium,* ***Zurich****,* Switzerland, 2020

**Session Chair & speaker:** *Research Program C Retreat, Grünstadt-Asselheim,* Germany, 2012

**Invited speaker:** *DKFZ Conference on Preventive Oncology,* ***Heidelberg****,* Germany, 2018

**Invited speaker:** *National Cancer Center,* ***Beijing****,* China, 2018

**Invited speaker:** *Zhejiang Academy of Medical Sciences (ZJAMS),* ***Hangzhou****,* China, 2017

**Invited speaker:** *Workshop on registry-based studies,* ***Ulm University****,* Germany, 2017

**Invited speaker:**Register-based studies on huge Swedish medical databases,***Heidelberg University****,* Germany, 2017

**Invited speaker:** *Progress in Cancer Research (PICR),* DKFZ*,* ***Heidelberg****,* Germany, 2016

**Invited speaker:** *Workshop on registry-based studies,* ***Ulm University****,* Germany, 2016

**Invited speaker:** *Current Research in Cancer Prevention,* ***Heidelberg****,* Germany, 2016

*American Association for Cancer Research (AACR) Annual Meeting*, ***New Orleans***, USA, 2016

*American Association for Cancer Research (AACR) Annual Meeting*, ***Philadelphia***, USA, 2015

*American Association for Cancer Research (AACR) Annual Meeting*, ***San Diego***, USA, 2014

**Invited speaker:** *Challenges & Chances in Prostate Cancer Res. Symposium,* ***Bonn****,* Germany, 2013

**Speaker:** *Familial Aspects of Cancer*, ***Cairns***, Australia, 2013

*American Association for Cancer Research (AACR) Annual Meeting*, ***Chicago***, USA, 2012

*7th International Symposium on Melanoma & Other Cutaneous Malignancies.* ***New York***, 2010

International Conference on Early Disease Detection and Prevention, ***Munich***, Germany, 2010

*The 28th International Epilepsy Congress*. ***Budapest***, Hungary, 2009

The *62nd Annual Meeting of the American Epilepsy Society, 2nd Biennial North American Regional Epilepsy Congress*. ***Seattle***, Washington, USA, 2008

*Clinical Oncological Society of Australia and the International Association of Cancer Registries Joint Scientific Meeting*. ***Sydney***, Australia, 2008

**Speaker:** *European Network of Cancer Registries (ENCR) General Meeting*. ***Slovenia***, 2007

**Speaker:** *29th Annual Meeting of International Association of Cancer Registries*. ***Slovenia***, 2007

**Speaker:** *Public defense of doctoral dissertation*. *Faculty of Medicine, University of Tampere.* ***Tampere***, Finland, 2007

*Opponent: Prof.* ***Max Parkin*** *from Oxford University, and International Agency for Research on Cancer, IARC*

***External Reviewer****: Prof.* ***Elisabete Weiderpass****, current* ***Director of IARC***

**Grants Awarded**

**Intramural Funding**

2013 – Pres My position and position of my senior staff were fully funded by our institute

2004 Tampere School of Public Health Research Grant, University of Tampere, Finland

2003 – Pres 10s of travel grants for conferences

**Extramural Funding**

2020 Scholarship for **a PhD student**, 4-year stipendium

2017 – 2020 Supervision costs for a PhD student (**several times**)

2017 Scholarship for **a PhD students**, 4-year stipendium

2017 Scholarship for **a PhD students**, 3-year salary

2017 Scholarship for **a PhD students**, 3-year stipendium

2016 Scholarship for **a PhD student**, 3-year stipendium

2003 – Pres Several travel grants for conferences

2007 – 2009 EVO grant from Tampere University Hospital, Finland

2007 Tampere City grant for doctoral dissertation, Finland

2005 DPPH grant, Doctoral Program in Public Health, Finland

2004 CIMO grant, Center for International Mobility, Finland

**Teaching Experiences**

2016 – Pres Teaching and supervising my PhD students, German Cancer Research Center (DKFZ), Germany

2018 – Pres All DKFZ PhD students, Research-based teaching in Progress in Cancer Research (PiCR) course, German Cancer Research Center (DKFZ), Germany

2014 Fit for Teaching - Introduction to Teaching and Learning at University level 1 + 2 (participation in an interactive course about how to teach)

2007 All PhD students, Epidemiology course, practical sessions at the School of Public Health, University of Tampere, Finland

2000 Hospital staff in the entire city, all levels from clerks to medical sub-specialists, Quality Improvement Course, Kashan University of Medical Sciences

**Supervision Tasks**

I have had several PhD students in my group (3 graduated, 1 is **Associate Professor** in a university), 1 is waiting for defense, and 1 joined in 2020 (3 received grade of **Great Distinction** for their dissertations). These are apart from several PhD students and postdocs that I was co-supervising in my previous positions. I supervise and teach my PhD in a routine basis following subjects:

* Basic epidemiology
* Cancer epidemiology
* Familial cancer
* Cancer screening
* Personalized cancer prevention (primary, secondary, and tertiary)
* SAS (statistical program) programming
* How to work with huge databases
* How to remotely work on databases that are on Swedish servers
* How to write excellent scientific articles
* How to make excellent scientific posters
* How to submit manuscripts and how to answer reviewers’ comments professionally
* How to apply for grants and awards
* How to make excellent scientific presentations
* How to make an excellent PhD dissertation

**Workshops**

Project **Management** in Action; Executing **Leadership**; Fit for **Teaching** - Introduction to Teaching and Learning at University level 1 + 2; **Communication** and Team Skills; **Grant Writing** - a hands-on training; Medical Education Technology; access to biomedical information resources; modern methods of medical education; evidence-based medicine; ICD-O-3 coding; etc.

# 

# Computer Skills

Professional user of SAS 9.4, Stata, SPSS (also familiar with R program & Plink), Microsoft Office (Excel, Access, Word, PowerPoint, & Outlook), Windows and Mac OS, OVID/Medline, Refworks, Reference Manager, EndNote X7, & Canreg Software for cancer registration, & data management

# Soft Skills

**Positive thinker**; **proactive**; initiative; **communicative**; team-player; multi-task; organized**; problem-solver;** result-oriented; **critical assessment**; negotiation; leadership; **Good Scientific/Epidemiology** **Practice**; Project manager; expert in **presentation at scientific meetings**

# Language Skills

**English**: Very fluent

**German**: Fluent

**Finnish**: Beginner

**Persian**: Native

Schematic CV

**** Medicine, epidemiology, epidemiologist, cancer epidemiology, cancer prevention, prevention, early detection, screening, risk factor, incidence, mortality, survival, personalized, risk, risk-adapted, risk-tailored, precision, cancer, neoplasm, oncology, malignancy, tumor, family, relative, family members, patients, first-degree relatives, second-degree relatives, half-sibling, parent, sibling, offspring, maternal, paternal, pedigree, familial, familial risk, familial cancer, genetic, hereditary, breast cancer, colorectal cancer, prostate cancer, gallbladder cancer, in situ, carcinoma, benign, head, director, coordinator, manager, leader, group leader, team leader, faculty member, research faculty, associate professor, professor, teaching, graduate students, leadership, supervisor, pharmacoepidemiology, postdoc, PhD, MD, university, degree, Nordic, Scandinavian, data science, real world data, real world evidence, evidence based, population-based, nationwide, cohort, cohort study, data analysis, funding, Finland, Germany, USA, UK, Canada, Switzerland, database, large-scale, long-lasting, computer, English, language, German, Finnish, communicative, team-player, initiative, creative, problem solver, SAS, SPSS, R program